Hims & Hers Health, Inc. HIMS is scheduled to report third-quarter 2025 results on Nov. 3, after the closing bell. In the last reported quarter, the company’s earnings per share (EPS) of 17 cents ...

Telehealth company Hims & Hers Health (NYSE:HIMS) in Q4 CY2025, with sales up 28.4% year on year to $617.8 million. On the ...

Maple Tree Capital, an investment management company, released its Q3 2025 investor letter. A copy of the letter can be downloaded here. The third quarter was mixed for Maple Tree Capital. The market ...

Throughout 2024, Hims & Hers demonstrated consistent top-line acceleration driven by new product introductions and broader consumer adoption. The company’s revenue grew from $260 million in Q1 2024 to ...

Hims & Hers Health, Inc.’s HIMS investors have been experiencing some short-term losses lately. The San Francisco, CA-based health and wellness platform’s stock has lost 39.2% compared with the ...

4 analysts have expressed a variety of opinions on Hims & Hers Health (NYSE:HIMS) over the past quarter, offering a diverse set of opinions from bullish to bearish. The table below provides a concise ...

CHONGQING, CHINA - MAY 04: In this photo illustration, the logo of Hims & Hers Health, Inc. is displayed on a smartphone screen, with the company's stock market performance and candlestick chart ...

Hims & Hers Health, Inc. (HIMS) presents a compelling risk-reward profile as bearish sentiment and regulatory concerns appear fully priced into the stock. HIMS is aggressively expanding its product ...

Hims & Hers Health is significantly undervalued, with the market underestimating its growth potential and international expansion opportunities. Geographical and product expansion, vertical ...